Toboroz
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT07587242· 3. fázis· Avidity Biosciences, Inc.· Forrás
Contact: Avidity Bioscience, Inc., A Novartis Company
Toboroz
Esketamine nasal spray (Spravato) for the treatment of therapy-resistant bipolar depression. An open-label pilot trial.
2023-508125-27-00· 2. fázis· Academisch Ziekenhuis Leiden· Forrás
Toboroz
Tolerogenic dendritic cell therapy in type 1 diabetes; a phase 1b safety and immunological effecitivity study
2023-508558-25-01· 1/2. fázis· Academisch Ziekenhuis Leiden· Forrás
Fut, nem toboroz
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A study of the safety and efficacy of MB-dNPM-1-TCR.1 in patients with relapsed or refractory AML.
2023-505806-41-00· 1/2. fázis· Miltenyi Biomedicine GmbH· Forrás
Toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
2023-503699-25-00· 3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Toboroz
MethMax trial
2023-507714-27-00· 4. fázis· Medical University of Vienna· Forrás
Toboroz
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
NCT06240143· 1/2. fázis· The Netherlands Cancer Institute· Forrás
Toboroz
Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
NCT05056220· 3. fázis· Aleksander Krag· Forrás
Contact: Minneke Coenraad
Toboroz
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
NCT05933057· 3. fázis· Italfarmaco· Forrás
Fut, nem toboroz
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744· 3. fázis· Genmab· Forrás
Toboroz
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690· 3. fázis· Aura Biosciences· Forrás
Fut, nem toboroz
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332· 2/3. fázis· IDEAYA Biosciences· Forrás
Fut, nem toboroz
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NCT05907954· 2. fázis· IDEAYA Biosciences· Forrás
Fut, nem toboroz
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976· 3. fázis· Genmab· Forrás
Fut, nem toboroz
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· 3. fázis· University Medical Center Groningen· Forrás
Meghívásos bevonás
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
NCT05374590· 2/3. fázis· argenx· Forrás
Fut, nem toboroz
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05283720· 2. fázis· Genmab· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
NCT04844866· 2. fázis· Miltenyi Biomedicine GmbH· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
NCT04464434· 4. fázis· UMC Utrecht· Forrás
Fut, nem toboroz
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
NCT03772028· 3. fázis· The Netherlands Cancer Institute· Forrás